
IMPROVE THE STANDARD OF CARE IN THE USA
Prevent avoidable deaths!
Prevent avoidable deaths!
Testing for DPD/DPYD deficiency prior to the start of chemotherapy with 5-FU (Fluorouracil) or Capecitabine (Xeloda) can reduce suffering and save lives.
Testing for DPD/DPYD deficiency prior to the start of chemotherapy with 5-FU or Capecitabine (Xeloda) can reduce suffering and save lives.
Testing for DPD/DPYD deficiency is becoming the standard of care across Europe and in select institutions in the US: it is time for it to become THE standard of care across all of the US.
Our Mission
To improve the standard of care in the United States for cancer patients undergoing fluoropyrimidine chemotherapy (5-FU and/or Capecitabine), through advocacy, education and research.